Source: Guideline 2004
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Rodríguez-Roisin, M.J. Krowka , Ph. Hervé, et al.. Pulmonary–Hepatic vascular Disorders (PHD). Guideline 2004

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary-Hepatic vascular Disorders (PHD) Source: Eur Respir J 2004; 24 : 861-880 Year: 2004 Clinical phenotypes in pulmonary emboli identified by cluster analysis Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Serum apelin 13 levels in patients with pulmonary embolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Population pharmacokinetics (PK) of riociguat in patients (pts) with renal and hepatic impairment Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Vascular endothelial growth factor (VEGF) as marker of pulmonary hypertension in children with asthma Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Characterization of circulating CD133+ progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Immune signatures in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Endothelial microparticles and progenitor cells in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Skeletal muscle impairment and proteomic profil in human pulmonary arterial hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Muscle function and physical activity in patients with idiopathic pulmonary arterial hypertension (IPAH) Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Outcomes in embolisations of pulmonary arterio-venous malformations Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Alteration of factors associated with coagulation in provoked pulmonary embolism Source: International Congress 2014 – Acute pulmonary embolism Year: 2014 Association between antiphospholipid antibody type and level and pulmonary manifestations in APS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Detection of hepatopulmonary syndrome in patients with liver cirrhosis using 3D contrast echocardiography Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Endothelial-to-mesenchymal transition in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Isolated hypocapnia: A sign not to be neglected Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014